Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Average Recommendation of “Hold” by Brokerages

Seaport Therapeutics, Inc. (NASDAQ:SPTX) has been given an average rating of “Hold” by the seven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $35.50.

SPTX has been the subject of several recent research reports. JPMorgan Chase & Co. assumed coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $42.00 target price for the company. UBS Group cut Seaport Therapeutics to a “sell” rating in a research report on Tuesday, June 9th. BNP Paribas Exane cut Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Stifel Nicolaus began coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Seaport Research Partners set a $42.00 price target on shares of Seaport Therapeutics in a research report on Tuesday, May 26th.

Insider Buying and Selling

In other Seaport Therapeutics news, Director Robert J. Hombach purchased 13,000 shares of the stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $18.14 per share, with a total value of $235,820.00. Following the completion of the transaction, the director owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc purchased 1,100,000 shares of the stock in a transaction dated Monday, May 4th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the transaction, the insider owned 6,294,951 shares of the company’s stock, valued at $113,309,118. The trade was a 21.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Seaport Therapeutics Price Performance

SPTX opened at $19.31 on Friday. Seaport Therapeutics has a 1 year low of $14.85 and a 1 year high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last issued its earnings results on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, topping the consensus estimate of ($10.64) by $0.30.